Across TCGA pan-cancer cohorts, MGAT4D Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MGAT4D data layer compared with 14 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MGAT4D Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MGAT4D expression acts as an unfavorable survival marker.
UCEC are the cancer types where MGAT4D Mutation most reproducibly stratifies survival.